Oncologists Urged to Take Proactive Approach When Discussing Ivermectin, Fenbendazole (2026)

Other · American Society of Clinical Oncology (ASCO) · June 17, 2026

American Society of Clinical Oncology (ASCO), 2026-06-17: ASCO's 2026 clinical notice, announced on its own site, advises oncologists that ivermectin and fenbendazole should not be used for cancer outside a well-designed clinical trial and urges routine asking about supplements and alternative therapies.

The American Society of Clinical Oncology (ASCO) cautions that ivermectin and fenbendazole should not be used to treat cancer, nor as an adjunct to established cancer therapies, outside the regulatory safeguards of a well-designed clinical trial.

Article body (unpaginated)

American Society of Clinical Oncology (ASCO), 2026-06-17: ASCO's 2026 clinical notice, announced on its own site, advises oncologists that ivermectin and fenbendazole should not be used for cancer outside a well-designed clinical trial and urges routine asking about supplements and alternative therapies. Study type: other.